Rare variants in genes that regulate the end regions of chromosomes — called telomeres — are linked with worse survival rates after lung transplant in pulmonary fibrosis (PF) patients, a study suggests. The study, “Lung Transplant Outcomes in Pulmonary Fibrosis Patients with Telomere-Related Gene Variants” was published in the…
News
Treatment with Ofev (nintedanib) can significantly extend the survival of patients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled data from six clinical trials shows. The analyis, conducted by an international research team, was published in the journal BMJ Open Respiratory Research, in an article titled “…
The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have awarded a physician scientist at Northwestern University this year’s research grant in idiopathic pulmonary fibrosis (IPF). Paul Andrew Reyfman, MD, was the recipient of the $100,000 fellowship, which will help fund his project, “Single Cell Transcriptomic…
Myth 1: If you can’t run with the big dogs, stay on the porch. Truth: In the words of the late great Dr. Martin Luther King Jr., “if you can’t fly then run, if you can’t run then walk, if you can’t walk then crawl, but whatever you do you…
Pliant Therapeutics has successfully completed a Phase 1 clinical study assessing its investigational therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF), with results supporting further clinical development of the compound. PLN-74809 is an oral small molecule that selectively inhibits integrins (signaling receptors) called αVβ6 and αVβ1. Results from earlier preclinical…
High levels of the protein vimentin in the lung tissue of patients with idiopathic pulmonary fibrosis (IPF) contribute to disease progression, an early study’s results show. Inhibiting vimentin can prevent fibroblasts — the cells responsible for the production and buildup of scar tissue (fibrosis) — from invading the lungs and producing…
Blood levels of immune cells called monocytes may help predict disease severity and determine the risk of poor outcomes in patients with idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, a retrospective study suggests. The study, “Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases:…
Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, especially from charitable organizations, a study finds. The study, “Retrospective Analysis of Medication Utilization and Clinical Outcomes in…
Envisia Genomic Classifier — a non-invasive diagnostic test developed by Veracyte and used as a complement to high-resolution computed tomography (HRCT) imaging — improves diagnosis of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) compared with HRCT alone, according to a recent study. The findings were published…
Quantification of so-called honeycombing areas (patches of cystic spaces) in the lungs seen through high-resolution computed tomography (HRCT) may be a predictor of mortality in people with idiopathic pulmonary fibrosis (IPF), according to a retrospective analysis. The study, “Quantitative CT analysis of honeycombing area predicts mortality in…
